Supreme Court restores mifepristone access

Good morning, healthcare professional.

The Supreme Court has restored access to the abortion pill mifepristone through telehealth and mail, temporarily overturning a lower court's restriction in a case that has significant implications for FDA regulatory authority. Meanwhile, the FDA has approved the first PROTAC-based therapy for breast cancer, marking a milestone in targeted protein degradation technology, and UCB has announced a $2.2 billion acquisition focused on bispecific antibodies for autoimmune diseases.

These developments highlight the intersection of regulatory policy, therapeutic innovation, and strategic consolidation shaping today's healthcare landscape. From courtroom decisions that affect drug access to novel treatment modalities reaching patients, the industry continues to navigate both legal uncertainty and scientific advancement.

In today's healthcare digest:

• Supreme Court ruling restores mifepristone access amid ongoing legal battle
• FDA approves Arvinas' first-in-class PROTAC therapy for breast cancer
• UCB acquires Candid Therapeutics for $2.2B to expand bispecifics portfolio
• Hantavirus outbreak on cruise ship raises public health concerns

Supreme Court Restores Mifepristone Access Amid Regulatory Battle

The Supreme Court has temporarily restored access to the abortion pill mifepristone through telehealth, mail, and pharmacies after a federal appeals court blocked its distribution. The decision comes as the case continues to raise questions about FDA authority and drug approval processes.

Unpacked:

• A federal appeals court initially blocked mailing of mifepristone, creating immediate access barriers for patients nationwide.
• Legal experts warn the case makes drug development riskier by allowing courts to second-guess FDA scientific determinations years after approval.
• The ruling affects not only abortion access but sets precedent for how courts can challenge regulatory decisions across all therapeutic areas.

FDA Approves First PROTAC Therapy for Breast Cancer

The FDA has approved Veppanu (vepdegestrant), developed by Arvinas and Pfizer, marking the first approval of a PROTAC-based drug for treating a specific breast cancer subtype. This accelerated approval validates a novel mechanism that degrades disease-causing proteins rather than simply inhibiting them.

Unpacked:

• PROTAC technology uses the body's natural protein disposal system to eliminate targeted proteins, offering advantages over traditional inhibitors.
• Veppanu targets estrogen receptor-positive, HER2-negative breast cancer with specific ESR1 mutations after prior endocrine therapy.
• The approval opens the door for additional PROTAC candidates across oncology and other disease areas in development pipelines.

UCB Bets $2.2B on Bispecifics with Candid Acquisition

UCB will acquire Candid Therapeutics for $2.2 billion, gaining access to bispecific antibody treatments for autoimmune diseases. The deal focuses on T-cell engagers and next-generation immunology platforms.

Unpacked:

• Candid's pipeline includes bispecific antibodies targeting B-cells and T-cells for conditions like lupus and rheumatoid arthritis.
• The acquisition reflects industry-wide momentum toward bispecific platforms that can simultaneously engage multiple disease targets.
• UCB continues building its immunology franchise following previous strategic investments in novel antibody engineering technologies.

Hantavirus Outbreak on Cruise Ship Raises Surveillance Questions

A suspected hantavirus outbreak on a cruise ship has prompted public health officials to issue warnings about the rare but serious rodent-borne illness. Health authorities have published educational guidance to help travelers understand transmission risks.

Unpacked:

• Hantavirus typically spreads through contact with rodent droppings, urine, or saliva in enclosed spaces with poor ventilation.
• The cruise ship setting is unusual for hantavirus transmission, which more commonly occurs in rural or wilderness environments.
• Public health experts view the outbreak as a warning sign for improved infectious disease surveillance in travel settings.

The Shortlist

• Cytokinetics reported positive results for Myqorzo in a study of non-obstructive hypertrophic cardiomyopathy, meeting twin efficacy goals.

• Johnson & Johnson is advancing its inflammatory bowel disease therapy despite a trial that showed no meaningful improvement over placebo.

• Cytospire raised $83 million in Series A funding to develop a novel gamma-delta T cell engager platform.

• Amgen is investing another $300 million in its Puerto Rico biologics manufacturing expansion.

• Novartis cut approximately 60 positions at its U.S. headquarters following earlier workforce reductions in March.